399 related articles for article (PubMed ID: 29739175)
1. Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases.
Oshima T; Miwa H
J Neurogastroenterol Motil; 2018 Jul; 24(3):334-344. PubMed ID: 29739175
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438).
Otake K; Sakurai Y; Nishida H; Fukui H; Tagawa Y; Yamasaki H; Karashima M; Otsuka K; Inatomi N
Adv Ther; 2016 Jul; 33(7):1140-57. PubMed ID: 27287852
[TBL] [Abstract][Full Text] [Related]
3. Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases.
Inatomi N; Matsukawa J; Sakurai Y; Otake K
Pharmacol Ther; 2016 Dec; 168():12-22. PubMed ID: 27514776
[TBL] [Abstract][Full Text] [Related]
4. The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.
Echizen H
Clin Pharmacokinet; 2016 Apr; 55(4):409-18. PubMed ID: 26369775
[TBL] [Abstract][Full Text] [Related]
5. The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase.
Scott DR; Munson KB; Marcus EA; Lambrecht NW; Sachs G
Aliment Pharmacol Ther; 2015 Dec; 42(11-12):1315-26. PubMed ID: 26423447
[TBL] [Abstract][Full Text] [Related]
6. Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data.
Marabotto E; Ziola S; Savarino V; Giannini EG; Furnari M; Bodini G; Zingone F; Ghisa M; Barberio B; Zentilin P; Savarino E
Clin Exp Gastroenterol; 2020; 13():99-104. PubMed ID: 32346304
[TBL] [Abstract][Full Text] [Related]
7. Vonoprazan fumarate for the management of acid-related diseases.
Martinucci I; Blandizzi C; Bodini G; Marabotto E; Savarino V; Marchi S; de Bortoli N; Savarino E
Expert Opin Pharmacother; 2017 Aug; 18(11):1145-1152. PubMed ID: 28657473
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacological characteristics and clinical efficacies of a novel potassium-competitive acid blocker, vonoprazan fumarate].
Matsukawa J; Inatomi N; Nishida H; Tsukimi Y
Nihon Yakurigaku Zasshi; 2018; 152(3):104-110. PubMed ID: 30185727
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of Acid-related Diseases Using Potassium-competitive Acid Blockers].
Choi YJ
Korean J Gastroenterol; 2022 Dec; 80(6):247-253. PubMed ID: 36567437
[TBL] [Abstract][Full Text] [Related]
10. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date.
Sugano K
Therap Adv Gastroenterol; 2018; 11():1756283X17745776. PubMed ID: 29383028
[TBL] [Abstract][Full Text] [Related]
11. Acid suppression therapy: where do we go from here?
Scarpignato C; Pelosini I; Di Mario F
Dig Dis; 2006; 24(1-2):11-46. PubMed ID: 16699262
[TBL] [Abstract][Full Text] [Related]
12. The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.
Yamashita H; Kanamori A; Kano C; Hashimura H; Matsumoto K; Tsujimae M; Yoshizaki T; Momose K; Obata D; Eguchi T; Fujita M; Okada A
Digestion; 2017; 96(1):52-59. PubMed ID: 28662503
[TBL] [Abstract][Full Text] [Related]
13. Vonoprazan: A New Potassium-Competitive Acid Blocker.
St Onge E; Phillips B
J Pharm Technol; 2023 Jun; 39(3):139-146. PubMed ID: 37323765
[No Abstract] [Full Text] [Related]
14. Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.
Yang X; Li Y; Sun Y; Zhang M; Guo C; Mirza IA; Li YQ
Dig Dis Sci; 2018 Feb; 63(2):302-311. PubMed ID: 29282636
[TBL] [Abstract][Full Text] [Related]
15. Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker.
Mori H; Suzuki H
J Neurogastroenterol Motil; 2019 Jan; 25(1):6-14. PubMed ID: 30504527
[TBL] [Abstract][Full Text] [Related]
16. Is the new potent acid-inhibitory drug vonoprazan effective for healing idiopathic peptic ulcers? A multicenter observational study in Akita Prefecture, Japan.
Sugawara K; Koizumi S; Horikawa Y; Mimori N; Tsuji T; Ishii H; Fujimori S; Onochi K; Watanabe H; Iijima K
J Gastroenterol; 2019 Nov; 54(11):963-971. PubMed ID: 31037448
[TBL] [Abstract][Full Text] [Related]
17. The Potential Benefits of Vonoprazan as
Miftahussurur M; Pratama Putra B; Yamaoka Y
Pharmaceuticals (Basel); 2020 Sep; 13(10):. PubMed ID: 32998241
[No Abstract] [Full Text] [Related]
18. Vonoprazan-based therapy for
Akazawa Y; Fukuda D; Fukuda Y
Therap Adv Gastroenterol; 2016 Nov; 9(6):845-852. PubMed ID: 27803739
[TBL] [Abstract][Full Text] [Related]
19. Potent Acid Suppression with PPIs and P-CABs: What's New?
Hunt RH; Scarpignato C
Curr Treat Options Gastroenterol; 2018 Dec; 16(4):570-590. PubMed ID: 30361857
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Vonoprazan for Helicobacter pylori Eradication.
Kiyotoki S; Nishikawa J; Sakaida I
Intern Med; 2020 Jan; 59(2):153-161. PubMed ID: 31243237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
